Microbot Medical® 旗下 Liberty® 血管内机器人系统获首项国际监管批准,开启商业化进程

美股速递
May 26

Microbot Medical Inc 迎来重要里程碑,其创新的 Liberty® 血管内机器人系统成功获得了首项国际监管批准,为公司将该系统推向全球市场进行商业化铺平了道路。这一突破性进展不仅标志着公司产品在监管合规方面取得关键认可,也预示着其先进技术在介入治疗领域迈入实际应用的新阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10